Active ingredientTivozanibCat. No. P-T136-001CAS 475108-18-0Family · Pharmaceutical analytical standards
Tivozanib
An oral tyrosine kinase inhibitor that blocks all three VEGF receptors, slowing the growth of new blood vessels in the tumour: approved in 2017 in Europe and in 2021 in the United States for advanced renal cell carcinoma. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It has an unusually long half-life for a kinase inhibitor taken by mouth: about five days.
Go to the active ingredient →Active ingredientTivozanibCat. No. P-T136-001CAS 475108-18-0
Isotopically labelledTivozanib-d6Cat. No. P-T136-002
Impurity2,4-Dichloro-1-nitrobenzeneCat. No. P-T136-003CAS 611-06-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.